Stock BIVI BIOVIE INC.
Add to a list
To use this feature you must be a member
Log inSign up

News BioVie Inc.

Equities

BIVI

US09074F2074

Market Closed - Nasdaq
Other stock markets
 01:30:00 26/06/2024 am IST 		5-day change 1st Jan Change
0.4488 USD -5.32% Intraday chart for BioVie Inc. 0.00% -64.38%
25/06 BioVie Inc. Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024 CI
22/05 BioVie Inc. Announces Its Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson?s Disease Patients CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
AQ
BioVie Inc. Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024
CI
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress
AQ
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
AQ
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
AQ
BioVie Inc. - Scientific Advisory Board to play pivotal role in guiding and accelerating bezisterim long COVID Phase 2b trial supported by an award from U.S. Department of Defense
AQ
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
AQ
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
AQ
BioVie Inc. Announces Its Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson?s Disease Patients
CI
BioVie Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024
CI
BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID
MT
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
AQ
BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim for the Treatment of Long COVID
CI
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints
AQ
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
AQ
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation
PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVI
PR
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)
BU
Shareholders that lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI
PR
The Gross Law Firm Notifies Shareholders of BioVie Inc. (BIVI) of a Class Action Lawsuit and an Upcoming Deadline
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BIVI Stock
  4. News BioVie Inc.